Durable response to palbociclib and letrozole in ovarian cancer with CDKN2A loss.

MLA

Frisone, Daniele, et al. “Durable Response to Palbociclib and Letrozole in Ovarian Cancer with CDKN2A Loss.” Cancer Biology & Therapy, vol. 21, no. 3, 2020, pp. 197–202. EBSCOhost, https://doi.org/10.1080/15384047.2019.1685291.

APA

Frisone, D., Charrier, M., Clement, S., Christinat, Y., Thouvenin, L., Homicsko, K., Michielin, O., Bodmer, A., Chappuis, P. O., McKee, T. A., & Tsantoulis, P. (2020). Durable response to palbociclib and letrozole in ovarian cancer with CDKN2A loss. Cancer Biology & Therapy, 21(3), 197–202. https://doi.org/10.1080/15384047.2019.1685291

Chicago

Frisone, Daniele, Melinda Charrier, Sophie Clement, Yann Christinat, Laure Thouvenin, Krisztian Homicsko, Olivier Michielin, et al. 2020. “Durable Response to Palbociclib and Letrozole in Ovarian Cancer with CDKN2A Loss.” Cancer Biology & Therapy 21 (3): 197–202. doi:10.1080/15384047.2019.1685291.